|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, CITED4 functions as a molecular switch in HB-EGF-induced growth control, and HB-EGF provides a novel therapeutic target for lung cancer intervention.
|
28092674 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.
|
21777670 |
2011 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that Mig-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines.
|
16819504 |
2007 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We searched for novel mechanistic biomarkers of AAH in an EGF transgenic disease model of lung cancer.
|
29960043 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, expression of BCR, which is required for EGFR protein degradation, was induced by EGF stimulation, suggesting a negative feedback loop in lung cancer.
|
17459062 |
2007 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, the EGF/DNA complex can deliver therapeutic genes to lung cancer cells by targeting to specific receptors.
|
8785711 |
1996 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.
|
31594212 |
2019 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the risk of lung cancer associated with EGF+61 A>G SNP in the Brazilian population.
|
30783937 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Instead, the lack of EGF receptor is frequently found in SCLC cell lines and is distinct from the other types of lung cancer.
|
3032412 |
1987 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that EGF doubles the proliferation (growth in soft agar as well as tumorigenicity in athymic mice) of A549 lung carcinoma cells and that the JNK2 isoform but not JNK1 is utilized for mediating the effects of EGF.
|
10022881 |
1999 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated the concentration-dependent negative regulatory effect of PIAS3 on STAT3 signaling and its capacity to decrease lung cancer proliferation and synergize with epidermal growth factor inhibition.
|
21497567 |
2011 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib.
|
27807951 |
2016 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In lung cancer cell lines, CpG island methylation was frequently detected for TIMP4 (64%), SOX18 (73%), EGF-like domain 7 (56%), CD105 (71%), SEMA2 (55%), RASSF1A (71%), p16 (56%) SLIT2 (100%) and TIMP3 (29%).
|
15911247 |
2005 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since a high percentage of lung adenocarcinoma in Asian female nonsmokers contains activating hotspot mutations in epidermal growth factor receptors (EGFR), we hypothesized that NAT2 polymorphisms might represent a risk factor in lung cancer with EGFR mutations.
|
18706736 |
2009 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we assessed the diagnostic value of epidermal growth factor (egf) and cancer antigens 125 (ca125) and 15-3 (ca15-3) in bronchoalveolar lavage fluid (balf) of lung cancer from 79 enrolled patients with suspected lung cancer.
|
28680284 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR ligands (e.g., EGF and TGFA) have been shown to be clinically associated with poor survival in lung cancer.
|
29662194 |
2018 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung cancer patients.
|
31132309 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance.
|
23071030 |
2012 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown dramatic effects against EGFR mutant lung cancer, patients become resistant by various mechanisms, including gatekeeper EGFR-T790M mutation, Met amplification, and HGF overexpression, thereafter relapsing.
|
22844075 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that EGF can induce EMT in human prostate and lung cancer cells and thus promote invasion and migration.
|
25124796 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
|
12867060 |
2003 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
|
16766261 |
2006 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the ability of NMB to cause transactivation of the epidermal growth factor (EGF) receptor in lung cancer cells.
|
20388507 |
2010 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we present evidence that TR3 was also induced by epidermal growth factor (EGF) and serum and was required for their mitogenic effect in lung cancer cells.
|
14612408 |
2003 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this proof-of-concept study, we report wide-field Raman detection of lung cancer using multimodal SERS nanoprobes specific to the EGF receptor family, both in vitro and in vivo.
|
25046405 |
2015 |